Top

Current Treatment Options in Cardiovascular Medicine

Published in:

01-08-2010 | Prevention

Treatment of Angina and Microvascular Coronary Dysfunction

Authors: Arang Samim, MD, Lynn Nugent, MD, Puja K. Mehta, MD, Chrisandra Shufelt, MD, MS, C. Noel Bairey Merz, MD

Published in: Current Treatment Options in Cardiovascular Medicine | Issue 4/2010

Opinion statement

Microvascular coronary dysfunction (MCD) is an increasingly recognized cause of cardiac ischemia and angina that is diagnosed more commonly in women. Patients with MCD present with the triad of persistent chest pain, ischemic changes on stress testing, and no obstructive coronary artery disease on cardiac catheterization. Data from the National Heart, Lung, and Blood Institute–sponsored Women’s Ischemia Syndrome Evaluation (WISE) study show that the diagnosis of MCD is not benign, with a 2.5% annual risk of adverse cardiac events including myocardial infarction, stroke, congestive heart failure, and death. The gold standard diagnostic test for MCD is the invasive coronary reactivity test (CRT), which uses acetylcholine, adenosine, and nitroglycerin to test endothelial-dependent and -independent microvascular and macrovascular coronary function. The CRT allows for diagnostic and treatment options as well as further risk stratification of patients for future cardiovascular events. Treatment of angina and MCD should be aimed at ischemia disease management to reduce the risk of adverse cardiac events, ameliorate symptoms to improve quality of life, and decrease morbidity from unnecessary and repeated cardiac catheterization in patients with open coronary arteries. A comprehensive treatment approach aimed at risk factor management, including lifestyle counseling regarding smoking cessation, nutrition, and physical activity, should be initiated. Current pharmacotherapy for MCD may include treatment of microvascular endothelial dysfunction (with statins, angiotensin-converting enzyme inhibitors, or low-dose aspirin), as well as treatment for angina and myocardial ischemia (with β-blockers, calcium channel blockers, nitrates, or ranolazine). Additional symptom management techniques may include tricyclic medication, enhanced external counterpulsation, hypnosis, and spinal cord stimulation. Although our current therapies are effective in treating angina and MCD, large randomized outcome trials are needed to optimize strategies to improve morbidity and mortality.

Sharaf BL, Pepine CJ, Kerensky RA, et al.: Detailed angiographic analysis of women with suspected ischemic chest pain (pilot phase data from the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation [WISE] Study Angiographic Core Laboratory). Am J Cardiol 2001, 87:937–941.CrossRefPubMed

Likoff W, Segal BL, Kasparian H: Paradox of normal selective coronary arteriograms in patients considered to have unmistakable coronary heart disease. N Engl J Med 1967, 267:1063–1066.

Pasternak RC, Thibault GE, DeSanctis RW, Hutter AM: Chest pain with angiographically insignificant coronary arterial obstruction: clinical presentation and long-term follow up. Am J Med 1980, 68:813–817.CrossRefPubMed

Reis SE, Holubkov R, Conrad Smith AJ, et al.: WISE Investigators: Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am Heart J 2001, B141(5):735–741.CrossRef

Johnson BD, Shaw LJ, Buchthal SD, et al.: Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease. Results from the National Institutes of Health–National Heart, Lung, and Blood Institute–sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation 2004, 109:2993–2999.CrossRefPubMed

Johnson BD, Shaw LJ, Pepine CJ, et al.: Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: results from the NIH-NHLBI-sponsored Women’s Ischaemia Syndrome Evaluation (WISE) study. Eur Heart J 2006, 27:1408–1415.CrossRefPubMed

7.•

Cannon R: Microvascular angina and the continuing dilemma of chest pain with normal coronary angiograms. J Am Coll Cardiol 2009, 54:877–887.CrossRefPubMed

Shaw LJ, Merz CN, Pepine CJ, et al.: Women’s Ischemia Syndrome Evaluation (WISE) Investigators: The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health–National Heart, Lung, and Blood Institute–sponsored Women’s Ischemia Syndrome Evaluation. Circulation 2006, 114(9):894–904.CrossRefPubMed

Asbury EA, Slattery C, Grant A, et al.: Cardiac rehabilitation for the treatment of women with chest pain and normal coronary arteries. Menopause 2008, 15:454–460.CrossRefPubMed

10.

Kayikcioglu M, Payzin S, Yavuzgil O, et al.: Benefits of statin treatment in cardiac syndrome-X1. Eur Heart J 2003, 24:1999–2005.CrossRefPubMed

11.

Kaski JC, Rosano G, Gavrielides S, et al.: Effects of angiotensin-converting enzyme inhibition on exercise-induced angina and ST segment depression in patients with microvascular angina. J Am Coll Cardiol 1994, 23:652–657.CrossRefPubMed

12.

Pizzi C, Manfrini O, Fontana F, Bugiardini R: Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac Syndrome X: role of superoxide dismutase activity. Circulation 2004, 109(1):53–58.CrossRefPubMed

13.

Jadhav S, Ferrell W, Greer IA, et al.: Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2006, 48(5):956–963.CrossRefPubMed

14.

Roque M, Heras M, Raig E, et al.: Short-term effects of transdermal oestrogen replacement therapy on coronary vascular reactivity in postmenopausal women with angina pectoris and normal results on coronary angiograms. J Am Coll Cardiol 1998, 31:139–143.CrossRefPubMed

15.

Hsia J, Langer RD, Manson JE, et al.: for the Women’s Health Initiative Investigators: Conjugated equine estrogens and coronary heart disease. Arch Intern Med 2006, 166:357–365.CrossRefPubMed

16.

Kronhaus KD, Lawson WE: Enhanced external counterpulsation is an effective treatment for syndrome X. Int J Cardiol 2009, 135(2):256–257.CrossRefPubMed

17.

National Cholesterol Education Program (NCEP) Expert Panel on Detection: Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the NCEP Expert Panel on Detection, Evaluation, Treatment, of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106(25):3143–3421.

18.

Parikh P, McDaniel MC, Ashen MD, et al.: Diets and cardiovascular disease: an evidence based assessment. J Am Coll Cardiol 2005, 45:1379–1387.CrossRefPubMed

19.

Baigent C, Blackwell L, Collins R, et al.: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009, 373:1849–1860.CrossRefPubMed

20.

Fraker Jr TD, Fihn SD, Gibbons RJ, et al.: American College of Cardiology; American Heart Association; American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group: 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina. Circulation 2007, 116(23):2762–2772.CrossRefPubMed

21.

Kaski JC, Rodriguez-Plaza L, Brown J, et al.: Efficacy of carvedilol (BM14, 190), a new beta-blocking drug with vasodilating properties, in exercise-induced ischemia. Am J Cardiol 1985, 56(1):35–40.CrossRefPubMed

22.

Matsuda Y, Akita H, Terashima M, et al.: Carvedilol improves endothelium-dependent dilation in patients with coronary artery disease. Am Heart J 2000, 140(5):753–759.CrossRefPubMed

23.

Sen N, Tavil Y, Erdamar H, et al.: Nebivolol therapy improves endothelial function and increases exercise tolerance in patients with cardiac syndrome X. Anadolu Kardiyol Derg 2009, 9(5):371–379.PubMed

24.

Lanza GA, Colonna G, Pasceri V, et al.: Atenolol versus amlodipine versus isosorbide-5-mononitrate on anginal symptoms in syndrome X. Am J Cardiol 1999, 84:854–856.CrossRefPubMed

25.

Bugiardini R, Borghi A, Biagetti L, Puddu P: Comparison of verapamil versus propranolol therapy in syndrome X. Am J Cardiol 1989, 63(5):286–290.CrossRefPubMed

26.

Bairey Merz CN, Eteiba W, Pepine CJ, et al.: Cardiac syndrome X: relation to microvascular angina and other conditions. Curr Cardiovasc Risk Rep 2007, 1:167–175.CrossRef

27.

Kaski JC, Rosano GM, Collins P, et al.: Cardiac syndrome X: clinical characteristics and left ventricular function. Long-term follow-up study. J Am Coll Cardiol 1995, 25:807–814.CrossRefPubMed

28.

Chapman BR: Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 2006, 113:2462–2472.CrossRef

29.

Chaitman BR: Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 2006, 113(20):2462–2472.CrossRefPubMed

30.

Caliskan M, Erdogan D, Gullu H, et al.: Effects of atorvastatin on coronary flow reserve in patients with slow coronary flow. Clin Cardiol 2007, 30(9):475–479.CrossRefPubMed

31.

Chen JW, Hsu NW, Wu TC, et al.: Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol 2002, 90(9):974–982.CrossRefPubMed

32.

Higuchi T, Abletshauser C, Nekolla SG, et al.: Effect of the angiotensin receptor blocker Valsartan on coronary microvascular flow reserve in moderately hypertensive patients with stable coronary artery disease. Microcirculation 2007, 8:805–812.CrossRef

33.

Cannon 3rd RO, Quyyumi AA, Mincemoyer R, et al.: Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 1994, 330:1411–1417.CrossRefPubMed

34.

Asbury EA, Kanji N, Ernst E, et al.: Autogenic training to manage symptomology in women with chest pain and normal coronary arteries. Menopause 2009, 16:60–65.CrossRefPubMed

35.

Valeriani M, Sestito A, Le Pera D, et al.: Abnormal cortical pain processing in patients with cardiac syndrome X. Eur Heart J 2005, 26:975–982.CrossRefPubMed

36.

Sestito A, Lanza GA, Le Pera D, et al.: Spinal cord stimulation normalizes abnormal cortical pain processing in patients with cardiac syndrome X. Pain 2008, 139:82–89.CrossRefPubMed

37.

Radovits T, Bomicke T, Kokeny G, et al.: The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus. Br J Pharmacol 2009, 156:909–919.CrossRefPubMed

38.

Piatti P, Fragasso G, Monti LD, et al.: Acute intravenous L-arginine infusion decreases endothelin-1 levels and improves endothelial function in patients with angina pectoris and normal coronary arteriograms: correlation with asymmetric dimethylarginine levels. Circulation 2003, 107(3):429–436.CrossRefPubMed

39.

Schulman SP, Becker LC, Kass DA, et al.: L-Arginine therapy in acute myocardial infarction. JAMA 2006, 295:58–64.CrossRefPubMed

Title: Treatment of Angina and Microvascular Coronary Dysfunction
Authors: Arang Samim, MD
Lynn Nugent, MD
Puja K. Mehta, MD
Chrisandra Shufelt, MD, MS
C. Noel Bairey Merz, MD
Publication date: 01-08-2010
Publisher: Current Science Inc.
Published in: Current Treatment Options in Cardiovascular Medicine / Issue 4/2010
Print ISSN: 1092-8464
Electronic ISSN: 1534-3189
DOI: https://doi.org/10.1007/s11936-010-0083-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Treatment of Angina and Microvascular Coronary Dysfunction

Opinion statement

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Opinion statement

Please log in to get access to this content

Other articles of this Issue 4/2010

Obstructive Sleep Apnea and Cardiovascular Disease

High-Density Lipoprotein Therapy: Is There Hope?

Therapeutic Approaches to Obesity

Do We Know When and How to Lower Lipoprotein(a)?

Exercise as a Treatment for the Risk of Cardiovascular Disease

Omega-3 Fatty Acids for Cardiovascular Disease Prevention

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page